Premium
Irinotecan as maintenance therapy in high‐risk hepatoblastoma
Author(s) -
Qayed Muna,
Powell Christie,
Morgan Elaine R.,
Haugen Maureen,
Katzenstein Howard M.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22408
Subject(s) - medicine , hepatoblastoma , irinotecan , oncology , maintenance therapy , intensive care medicine , chemotherapy , cancer , colorectal cancer
Children with high‐risk hepatoblastoma (metastatic disease or a low alpha‐fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1‐ to 2‐year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high‐risk and recurrent HB patients is warranted. Pediatr Blood Cancer 2010;54:761–763. © 2009 Wiley‐Liss, Inc.